FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 240 filers reported holding FATE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $216,208 | -88.3% | 101,985 | -73.8% | 0.00% | -85.7% |
Q2 2023 | $1,849,508 | -0.0% | 388,552 | +19.7% | 0.01% | -74.1% |
Q1 2023 | $1,849,690 | +292.5% | 324,507 | +594.8% | 0.03% | +200.0% |
Q4 2022 | $471,253 | +12.5% | 46,705 | +149.8% | 0.01% | +12.5% |
Q3 2022 | $419,000 | -60.2% | 18,700 | -31.2% | 0.01% | -71.4% |
Q1 2022 | $1,054,000 | +294.8% | 27,175 | +503.2% | 0.03% | +250.0% |
Q3 2021 | $267,000 | -65.1% | 4,505 | -46.4% | 0.01% | -84.3% |
Q4 2020 | $765,000 | – | 8,410 | – | 0.05% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Polaris Venture Management Co. V, L.L.C. | 569,889 | $46,987,000 | 60.92% |
Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $278,604,000 | 36.08% |
Darwin Global Management, Ltd. | 1,370,133 | $112,967,000 | 22.12% |
Redmile Group, LLC | 12,957,222 | $1,068,323,000 | 15.05% |
Copernicus Capital Management, LLC | 8,000 | $660,000 | 10.66% |
Casdin Capital, LLC | 3,400,000 | $280,330,000 | 8.35% |
Grosvenor Holdings, L.L.C. | 1,123,576 | $92,639,000 | 6.81% |
DAFNA Capital Management LLC | 314,360 | $25,919,000 | 6.15% |
Ally Bridge Group (NY) LLC | 270,000 | $22,262,000 | 4.27% |
Ghost Tree Capital, LLC | 185,000 | $15,253,000 | 3.58% |